If You Invested in Scientific Ind (SCND)

Scientific Industries, Inc. (OTCQB: SCND) is a life science tool provider and manufacturing company focused on analytical and laboratory equipment. The company is described in its public communications as a developer of digitally simplified bioprocessing products, vision-based pill counters, and weighing instruments, serving research and healthcare environments. Its products are generally used in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies.

Core Business and Product Lines

According to multiple company press releases, Scientific Industries designs, manufactures, and markets laboratory and bioprocessing equipment. The company highlights several key product families:

• DOTS bioprocessing systems – real-time bioprocessing platforms referred to as the DOTS or DOTS MPS platform. Company disclosures state that DOTS is used for bioprocess development and is positioned to support synthetic biology, biomanufacturing, and digital biology workflows.
• VIVID vision-based pill counters – automated pill counting systems under the VIVID brand, including the VIVID WORKSTATION and a second-generation VIVID-One line scheduled for launch in the first quarter of calendar year 2026. These systems use machine learning and AI-enabled features for pharmacy automation, including prescription label documentation and verification.
• Torbal weighing products – weighing instruments under the Torbal brand, described as part of the company’s Benchtop Laboratory Equipment Operations. Torbal Division sales are repeatedly cited in the company’s financial updates.
• Laboratory equipment legacy products – prior communications reference the world‑renowned Vortex‑Genie 2 mixer and a Genie Division within the Benchtop Laboratory Equipment Operations. An 8‑K/A filing and subsequent press releases note that substantially all assets of the Genie Division, including the Genie line of products, were sold to Troemner, LLC, an affiliate of OHAUS Corporation, under an Asset Purchase Agreement dated August 7, 2025.

Strategic Focus and Business Transformation

In an August 7, 2025 news release, Scientific Industries stated that it has completed a strategic refocus by divesting its Genie Division and reallocating capital to accelerate growth of two data-driven business platforms: pharmacy automation and bioprocessing. The company describes itself as transforming into a deep‑tech, AI‑enabling company with SaaS‑enabled, data‑driven intellectual property models and integrated hardware/software platforms.

The same release explains that the Torbal division has evolved from analog pharmacy scales to a cloud‑based pharmacy automation platform centered on the VIVID automated pill counters. The company reports that its first VIVID automated pill counter was launched in 2020 and that the platform has expanded to three devices, including the VIVID Workstation, which is characterized as a cloud‑connected automated pill counting solution.

Scientific Industries also identifies Scientific Bioprocessing as a core platform that is “pioneering the digitization of analog bioproduction” with the DOTS platform, which converts biological signals into machine‑readable data for bioprocessing applications. Company commentary links this platform to synthetic biology, biomanufacturing, and laboratory digitization markets.

Operations and Segments

In its quarterly financial press releases, Scientific Industries discusses two primary operational groupings:

• Benchtop Laboratory Equipment Operations – historically including the Genie and Torbal divisions. After the August 7, 2025 sale of the Genie Division assets to Troemner, LLC, the company states in its 8‑K/A filing that it will continue to operate the Torbal Division of its Benchtop Laboratory Equipment Operations out of Bohemia, New York.
• Bioprocessing Systems Operations – centered on the DOTS MPS bioprocessing platform. Company disclosures describe this platform as supporting parallel bioprocessing, including applications in microbial and mammalian cell culture, and as a source of data for AI and digital biology.

Press releases across 2025 repeatedly reference revenues and gross margins for these operations, as well as trends such as increased Torbal Division sales and periods of softness in Bioprocessing Systems revenues due to market conditions and customer budgets. These operational discussions are presented in the company’s own financial communications and SEC‑related disclosures.

Technology Orientation and AI Features

Scientific Industries’ public statements emphasize a shift toward AI‑enabled and data‑driven platforms. In its August 19, 2025 and November 19, 2025 earnings releases, the company notes:

• The VIVID line of automated pill counters is described as the company’s first product line enabled by machine learning, with a pill library trained on thousands of pill images.
• The VIVID WORKSTATION is reported to include AI‑powered capabilities, including a prescription label documentation and verification feature.
• The DOTS MPS platform is described as supporting real‑time sensing and multiparameter monitoring in shake flasks and other bioprocessing contexts, with company commentary linking it to AI‑driven and digital biology workflows.

In an April 22, 2025 press release about a private placement, the company states that DOTS MPS is intended to create a standard in parallel bioprocessing by delivering structured, reliable, and repeatable data in shake flasks, which it identifies as a widely used reaction vessel in science.

Customers and End‑Markets

Across several “About Scientific Industries” sections in its news releases, the company explains that its products are generally used for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. Other releases specifically refer to use in R&D laboratories for synthetic biology and in pharmacies and industries requiring weighing products.

In its pharmacy automation communications, Scientific Industries highlights independent retail pharmacies as a key market for the VIVID platform. The company also notes that its DOTS platform is used in projects with industrial and academic customers, including biotech companies and university research groups, as described in its 2025 quarterly updates.

Capital and Corporate Actions

Scientific Industries’ SEC filings and press releases describe several notable corporate and capital actions:

• Divestiture of Genie Division – An 8‑K/A dated December 5, 2025, and an August 7, 2025 press release describe an Asset Purchase Agreement under which the company sold substantially all assets of its Genie Division to Troemner, LLC, a Delaware limited company affiliated with OHAUS Corporation. The purchase price consisted of a cash payment subject to working capital adjustments and a potential earn‑out, and the company agreed to provide supply and transition services for a limited period.
• Equity financing – A press release dated April 22, 2025 reports that the company completed a private placement of common stock and warrants to support advancement of the DOTS platform and general corporate use.
• Proxy and governance matters – A Definitive Proxy Statement on Schedule 14A filed December 29, 2025 provides notice of the 2024 Annual Meeting of Shareholders to be held in January 2026, including proposals related to director elections, an amendment to the 2022 Equity Incentive Plan, and ratification of the independent registered public accounting firm.

Regulatory Filings and Trading

Scientific Industries files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑Q, 10‑K, 8‑K, and proxy statements. The company’s securities trade on the OTCQB market under the symbol SCND, as stated in multiple press releases. A Form 12b‑25 (NT 10‑Q) dated November 14, 2025 notes a brief delay in filing the quarterly report for the period ended September 30, 2025, citing the need for additional time to complete financial statements.

Use Cases and Applications

Based on the company’s own descriptions, Scientific Industries’ products support several types of users and applications:

• Research laboratories – laboratory equipment and DOTS bioprocessing systems used for research in universities, hospitals, pharmaceutical companies, and medical device manufacturers.
• Pharmacies – VIVID vision‑based pill counters and Torbal weighing products used in pharmacy workflows, including automated pill counting and prescription documentation.
• Synthetic biology and bioprocess development – DOTS MPS platform deployments in R&D laboratories focused on synthetic biology and bioprocess optimization, as referenced in company communications about external projects and peer‑reviewed validation.

Risk and Forward‑Looking Statements

The company’s press releases include safe harbor statements indicating that forward‑looking comments about future events, performance, or financial results involve uncertainties and risks, and refer readers to the company’s SEC reports, including its annual report on Form 10‑K, for additional information about such risks.

Summary

In summary, Scientific Industries, Inc. is described in its own public disclosures as a manufacturing and life science tools company that has shifted its strategic focus toward AI‑enabled pharmacy automation and data‑driven bioprocessing platforms. Through its DOTS bioprocessing systems, VIVID pill counters, and Torbal weighing products, the company serves laboratories and pharmacies that require analytical, bioprocessing, and pill‑counting capabilities, with a stated emphasis on digital and cloud‑connected solutions.